Day: February 7, 2020

NEW YORK, Feb. 07, 2020 (GLOBE NEWSWIRE) — The Madison Square Garden Company (NYSE: MSG) today reported financial results for the fiscal second quarter ended December 31, 2019.For the fiscal 2020 second quarter, the Company generated revenues of $628.8 million, a decrease of 1% as compared to the prior year quarter.  The Company also generated operating income of $80.8 million, an increase of 3%, and adjusted operating income of $126.9 million, a decrease of 3%, both as compared to the prior year quarter.(1)(2)  This primarily reflects growth at both the MSG Sports and MSG Entertainment segments, offset by higher expenses in Corporate and Other, mainly the result of the MSG Sphere initiative and the proposed spin-off of the Company’s Entertainment business, partially offset by a decrease in employee compensation...

Paul Walker of New Enterprise Associates is appointed to the Board of DirectorsCAMBRIDGE, Mass., Feb. 07, 2020 (GLOBE NEWSWIRE) — Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that Paul Walker has been appointed to the Company’s Board of Directors, and Dr. Ali Behbahani has been appointed as a Board Observer, effective February 6, 2020. “We are delighted to welcome Mr. Walker to the Board of Directors and Dr. Behbahani as a Board Observer, and look forward to their guidance as we work to bring to patients our CD47 programs,” stated Dr. Robert Kirkman, Executive Chair of Trillium Therapeutics.“We are excited about Trillium’s...

CRANBURY, N.J., Feb. 07, 2020 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), a global, patient centric biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that one oral presentation and nine posters highlighting its development programs for Lysosomal Disorders will be included at the 16th Annual WORLDSymposium™ 2020, to be held February 10-13, 2020 in Orlando, FL.Oral Platform Presentations:Batten Disease:Single-dose AAV9-CLN6 gene transfer stabilizes motor and language function in CLN6-type Batten disease: interim results from the first clinical gene therapy trial – Emily de los Reyes, MD, Pediatric Neurology, Nationwide Children’s Hospital, Columbus, OH, USA (Thursday, February 13 at 8:30 a.m. EST)Poster Session: Monday, February 10,...

NEW HAVEN, Conn., Feb. 07, 2020 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at the BIO CEO & Investor Conference being held February 10 – 11, 2020 in New York City.Presentation Details:Event: BIO CEO & Investor ConferenceDate: Tuesday, February 11, 2020Time: 3:00 p.m. ETA live webcast of the presentation and the accompanying presentation materials that will be discussed will be accessible through the Investors section of the Company’s website at www.bioxceltherapeutics.com. Following...

BANNOCKBURN, Ill., Feb. 07, 2020 (GLOBE NEWSWIRE) — Stericycle, Inc. (Nasdaq: SRCL) today announced that it has entered into a definitive agreement to sell its Domestic Environmental Solutions business, excluding the healthcare customer and unused consumer pharmaceutical take-back services, to Harsco Corporation (NYSE: HSC) for $462.5 million in cash, subject to customary adjustments set forth in the agreement.The transaction includes Stericycle’s Domestic Environmental Solutions business including Manufacturing and Industrial Services and the retail portion of Hazardous Waste Services, which together employ approximately 2,000 team members across 61 facilities.  Stericycle will continue to offer solutions for unused consumer pharmaceutical take-back services and provide hazardous waste services to healthcare customers. ...

NOVA LIMA, Brazil, Feb. 07, 2020 (GLOBE NEWSWIRE) — Afya Limited, or Afya (Nasdaq: AFYA), today announced the pricing of a follow-on public offering of 12,426,740 Class A common shares at a public offering price of $27.50 per share, consisting of 3,019,928 Class A common shares offered by Afya, and 9,406,812 Class A common shares offered by certain selling shareholders of Afya (the “Selling Shareholders”), including Crescera Educacional II Fundo de Investimento em Participações Multiestratégia (“Crescera”), pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (“SEC”). The offering is expected to close on February 11, 2020. In addition, Afya and Crescera have granted the underwriters a 30-day option to purchase up...

The Cline Medical Centre in Nanaimo is the Eighth Authorized PoNS Treatment™ Clinic in Canada.NEWTOWN, Pa., Feb. 07, 2020 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq: HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announces the authorization of their eighth PoNS Treatment™ center in Nanaimo, British Columbia (BC), The addition of the Clinic Medical Centre (“CMC”) in Nanaimo further increases access to PoNS Treatment across Canada. Cline Medical Centre is a leading integrative and functional medicine healthcare facility located at 2090 Skaha Drive, Nanaimo, BC.About Helius Medical Technologies, Inc.Helius Medical Technologies is a neurotech company focused on neurological wellness.  The Company’s purpose...

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2020 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the pricing of its underwritten public offering of 2,500,000 shares of common stock at a public offering price of $30.00 per share.In addition, the underwriters have been granted a 30-day option to purchase up to an additional 375,000 shares of common stock at the public offering price, less the underwriting discount. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by RAPT, are expected to be $75.0 million, excluding...

SASKATOON, Saskatchewan, Feb. 07, 2020 (GLOBE NEWSWIRE) — Cameco (TSX: CCO; NYSE: CCJ) today reported its consolidated financial and operating results for the fourth quarter and year ended December 31, 2019 in accordance with International Financial Reporting Standards (IFRS).“As expected, we had a strong finish to 2019,” said Tim Gitzel, Cameco’s president and CEO. “We delivered 14 million pounds of uranium in the fourth quarter, and, in 2019, we generated $527 million in cash from operations, demonstrating our financial resilience.“We continue to do what we said we would do, and our results and outlook for 2020 are a direct result of our deliberate, value-oriented strategy. We are executing on all strategic fronts; operational, marketing and financial. We added just over 36 million pounds of deliveries...

BROOKFIELD NEWS, Feb. 07, 2020 (GLOBE NEWSWIRE) — Brookfield Asset Management Inc. (“Brookfield”) (NYSE: BAM, TSX: BAM.A) announced today the closing of its latest flagship global infrastructure fund, Brookfield Infrastructure Fund IV (“BIF IV” or the “Fund”), with total equity commitments of $20 billion.Based on strong investor demand, BIF IV attracted total capital commitments exceeding the original $17 billion fundraising target. BIF IV’s predecessor fund closed in 2016 with $14 billion of total capital commitments.Over the last 24 months, Brookfield has raised more than $50 billion across its flagship private fund strategies, including the close of its flagship real estate fund, Brookfield Strategic Real Estate Partners III, at $15 billion, and its flagship private equity...